CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Up 2.3%

CRISPR Therapeutics AG (NASDAQ:CRSP) shares traded up 2.3% during trading on Friday . The stock traded as high as $58.45 and last traded at $56.32. 579,291 shares were traded during trading, a decline of 67% from the average session volume of 1,761,138 shares. The stock had previously closed at $55.07.

Wall Street Analysts Forecast Growth

CRSP has been the subject of a number of recent research reports. Royal Bank of Canada lifted their price objective on shares of CRISPR Therapeutics from $57.00 to $66.00 and gave the stock a “sector perform” rating in a research note on Thursday, February 22nd. Morgan Stanley lifted their price target on shares of CRISPR Therapeutics from $46.00 to $48.00 and gave the stock an “underweight” rating in a research note on Monday, February 26th. Needham & Company LLC reissued a “buy” rating and issued a $90.00 price objective on shares of CRISPR Therapeutics in a research report on Thursday, April 11th. Citigroup boosted their target price on CRISPR Therapeutics from $88.00 to $89.00 and gave the company a “buy” rating in a research report on Thursday, April 18th. Finally, Mizuho increased their price target on CRISPR Therapeutics from $82.00 to $99.00 and gave the stock a “buy” rating in a report on Wednesday, March 6th. Three investment analysts have rated the stock with a sell rating, six have issued a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $76.29.

CRISPR Therapeutics Stock Up 1.5 %

The company has a market cap of $4.74 billion, a P/E ratio of -28.52 and a beta of 1.80. The business’s 50 day moving average is $67.75 and its 200 day moving average is $64.31.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Wednesday, February 21st. The company reported $1.10 EPS for the quarter, topping the consensus estimate of $0.15 by $0.95. The firm had revenue of $201.20 million for the quarter, compared to the consensus estimate of $148.72 million. During the same quarter last year, the firm earned ($1.41) EPS. The company’s revenue was up 3253.3% compared to the same quarter last year. As a group, equities research analysts forecast that CRISPR Therapeutics AG will post -6.24 EPS for the current year.

Insider Activity

In related news, General Counsel James R. Kasinger sold 1,913 shares of CRISPR Therapeutics stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $79.67, for a total value of $152,408.71. Following the completion of the sale, the general counsel now directly owns 57,371 shares in the company, valued at approximately $4,570,747.57. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, General Counsel James R. Kasinger sold 2,801 shares of the stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $78.26, for a total value of $219,206.26. Following the transaction, the general counsel now directly owns 60,070 shares of the company’s stock, valued at $4,701,078.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, General Counsel James R. Kasinger sold 1,913 shares of the firm’s stock in a transaction dated Tuesday, February 20th. The stock was sold at an average price of $79.67, for a total value of $152,408.71. Following the completion of the transaction, the general counsel now owns 57,371 shares of the company’s stock, valued at $4,570,747.57. The disclosure for this sale can be found here. Insiders have sold a total of 83,992 shares of company stock worth $6,132,335 over the last 90 days. 4.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On CRISPR Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Riggs Asset Managment Co. Inc. increased its stake in shares of CRISPR Therapeutics by 66.7% in the first quarter. Riggs Asset Managment Co. Inc. now owns 500 shares of the company’s stock worth $34,000 after acquiring an additional 200 shares during the period. Signaturefd LLC raised its stake in shares of CRISPR Therapeutics by 12.5% during the 3rd quarter. Signaturefd LLC now owns 2,124 shares of the company’s stock valued at $96,000 after buying an additional 236 shares during the last quarter. Itau Unibanco Holding S.A. boosted its stake in shares of CRISPR Therapeutics by 10.8% in the third quarter. Itau Unibanco Holding S.A. now owns 2,521 shares of the company’s stock worth $114,000 after buying an additional 245 shares during the last quarter. Spire Wealth Management raised its position in CRISPR Therapeutics by 32.7% during the third quarter. Spire Wealth Management now owns 1,052 shares of the company’s stock valued at $48,000 after acquiring an additional 259 shares in the last quarter. Finally, CWM LLC lifted its holdings in CRISPR Therapeutics by 80.7% in the third quarter. CWM LLC now owns 582 shares of the company’s stock valued at $26,000 after acquiring an additional 260 shares during the period. Institutional investors and hedge funds own 69.20% of the company’s stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.